ReviewFrontiers in microbiology2018
Challenges and Promises for Planning Future Clinical Research Into Bacteriophage Therapy Against
Review in Frontiers in microbiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 48 citations in OpenAlex.
- Phage Therapy Enhanced by Using Engineered Bacteriophages: A Powerful Antibacterial Tool to Address the Dilemma Posed by Multidrug-Resistant Bacterial Infections.International journal of molecular sciences · 2026Review
- Short-Term Bacteriophage Exposure Is Associated with Shifts in Antibiotic Susceptibility Profiles of ClinicalMicroorganisms · 2026Article
- Advances in Ciprofloxacin Derivatives: Emerging Strategies to Combat Antimicrobial Resistance.Topics in current chemistry (Cham) · 2026Review
- Host-Pathogen Interactions in Cystic Fibrosis Lung Disease: Adaptation, Persistence, and Clinical Implications ofPathogens (Basel, Switzerland) · 2026Review
- Detectable effects of bacterial phylogeny on virulence but not phage efficacy in anISME communications · 2026Article
- Isolation and characterization of new lytic bacteriophage PSA-KC1 against Pseudomonas aeruginosa isolates from cystic fibrosis patients.Scientific reports · 2025Article
- Frontiers in superbug management: innovating approaches to combat antimicrobial resistance.Archives of microbiology · 2025Review
- Genomic Insights into and Lytic Potential of Native Bacteriophages M8-2 and M8-3 Against Clinically Relevant Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2025Article
- Interlaboratory comparison ofJournal of clinical microbiology · 2023Article
- Current knowledge in the use of bacteriophages to combat infections caused by Pseudomonas aeruginosa in cystic fibrosis.Folia microbiologica · 2023Review
- Drugs, Drugs, Drugs: Current Treatment Paradigms in Cystic Fibrosis Airway Infections.Journal of the Pediatric Infectious Diseases Society · 2022Review
- In Vitro Techniques and Measurements of Phage Characteristics That Are Important for Phage Therapy Success.Viruses · 2022Review
- Parallel evolution ofeLife · 2022Article
- Novel Bacteriophages Show Activity against Selected Australian Clinical Strains ofMicroorganisms · 2022Article
- A Shaving Proteomic Approach to Unveil Surface Proteins Modulation of Multi-Drug ResistantFrontiers in medicine · 2022Article
- Isolation and characterization of a lytic bacteriophage against Pseudomonas aeruginosa.Scientific reports · 2021Article
- Advances in Bacteriophage Therapy against Relevant MultiDrug-Resistant Pathogens.Antibiotics (Basel, Switzerland) · 2021Review
- In Vitro Newly Isolated Environmental Phage Activity against Biofilms Preformed byMicroorganisms · 2021Article
- Methods for Extraction and Detection of Pf Bacteriophage DNA from the Sputum of Patients with Cystic Fibrosis.PHAGE (New Rochelle, N.Y.) · 2020Article
- Combined Bacteriophage and Antibiotic Treatment PreventsFrontiers in microbiology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although early aggressive and prolonged treatment with specific antibiotics can extend survival in patients with cystic fibrosis (CF) colonized by opportunistic
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.